Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,206.80 30.83 0.97%
FTSE 100 6,721.16 46.42 0.70%
DAX 9,643.00 98.81 1.04%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Optimer Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference



 Optimer Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare
                                  Conference

PR Newswire

JERSEY CITY, N.J., Dec. 20, 2012

JERSEY CITY, N.J., Dec. 20, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) today announced that the Company will present at the 31^st
Annual J.P. Morgan Healthcare conference on Tuesday, January 8, 2013 at 8:00
AM Pacific Time and provide a business overview and update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors
page of the Company's website at www.optimerpharma.com.  Replays of the
presentation will be available at the same location for 30 days following the
conference.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin)
tablets, an FDA-approved macrolide antibacterial drug for the treatment
of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada.  Optimer also
received marketing authorization for fidaxomicin tablets in the European
Union where its partner, Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™.  The Company is exploring
marketing authorization in other parts of the world where C. difficile has
emerged as a serious health problem, including Asia. Additional information
can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark, Senior Vice President
(619) 849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Website: http://www.optimerpharma.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement